BioScience Health Innovations, Inc. (BHIC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 2M 4M 6M Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q4 '23: 597.6K Q1 '24: 842.9K Q2 '24: 1.2M Q3 '24: 1.5M Q4 '24: 1.8M Q1 '25: 2.8M Q2 '25: 4.2M Q3 '25: 4.7M Q4 '25: 5.7M Q1 '26: 5.2M Q2 '26: 4.5M Q1 '21 Q4 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 1.5M 3M 4.5M Q4 '22: 59.6K Q1 '23: 87K Q2 '23: 139.9K Q3 '23: 283.9K Q4 '23: 484.4K Q1 '24: 691.6K Q2 '24: 942K Q3 '24: 1.2M Q4 '24: 1.3M Q1 '25: 2M Q2 '25: 2.7M Q3 '25: 3M Q4 '25: 3.2M Q1 '26: 2.8M Q2 '26: 2.4M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income TTM

-700K -350K 0 350K 700K 1.1M Q3 '20: -7.7K Q4 '20: -13.3K Q1 '21: -24K Q2 '21: -24.4K Q3 '21: -25.6K Q4 '21: -34.1K Q1 '22: -47.7K Q4 '23: -251.5K Q1 '24: -234.2K Q2 '24: -74.7K Q3 '24: 38.7K Q4 '24: 87K Q1 '25: 567.2K Q2 '25: 950.7K Q3 '25: 885.7K Q4 '25: 719.1K Q1 '26: 62.3K Q2 '26: -613.2K Q1 '21 Q4 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-700K -350K 0 350K 700K 1.1M Q3 '20: -7.7K Q4 '20: -13.3K Q1 '21: -24K Q2 '21: -24.4K Q3 '21: -25.6K Q4 '21: -34.1K Q1 '22: -39K Q4 '23: -251.5K Q1 '24: -234.2K Q2 '24: -74.7K Q3 '24: 38.7K Q4 '24: 87K Q1 '25: 567.2K Q2 '25: 950.7K Q3 '25: 885.7K Q4 '25: 642.1K Q1 '26: -14.6K Q2 '26: -658.1K Q1 '21 Q4 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 900K 1.8M 2.7M Q4 '22: 9.7K Q1 '23: 14.4K Q2 '23: 22.9K Q3 '23: 51.4K Q4 '23: 113.2K Q1 '24: 151.3K Q2 '24: 215.6K Q3 '24: 332K Q4 '24: 536.1K Q1 '25: 824.2K Q2 '25: 1.4M Q3 '25: 1.7M Q4 '25: 2.4M Q1 '26: 2.4M Q2 '26: 2.1M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-1.8M -1.2M -600K 0 600K 1.2M 1.8M Q3 '20: -7.7K Q4 '20: -2.1K Q1 '21: -25.8K Q2 '21: -24.4K Q3 '21: -29.4K Q4 '21: -34.8K Q1 '22: -42.1K Q4 '23: -307.8K Q1 '24: -289.2K Q2 '24: -105.6K Q3 '24: 17K Q4 '24: 23.2K Q1 '25: 399.5K Q2 '25: 615.2K Q3 '25: 222.6K Q4 '25: 172.2K Q1 '26: -708.2K Q2 '26: -1.5M Q1 '21 Q4 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '22: 5.5M Q1 '23: 5.5M Q3 '23: 40.4M Q1 '24: 41.4M Q2 '24: 42M Q3 '24: 10.9M Q1 '25: 44.3M Q2 '25: 11.4M Q3 '25: 11M Q1 '26: 11.4M Q2 '26: 11.7M Q1 '22 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.05 -0.03 0.00 0.03 0.05 0.08 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '24: 0.00 Q3 '24: 0.01 Q4 '24: 0.01 Q1 '25: 0.02 Q2 '25: 0.06 Q3 '25: 0.05 Q4 '25: 0.06 Q1 '26: 0.03 Q2 '26: -0.03 Q4 '20 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.